Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Neuroone Medical Technologies (NMTC) FCF Margin (2020 - 2025)

Neuroone Medical Technologies (NMTC) has disclosed FCF Margin for 11 consecutive years, with 109.13% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, FCF Margin fell 11473.0% year-over-year to 109.13%, compared with a TTM value of 71.28% through Dec 2025, up 5225.0%, and an annual FY2025 reading of 32.09%, up 29030.0% over the prior year.
  • FCF Margin was 109.13% for Q4 2025 at Neuroone Medical Technologies, down from 56.05% in the prior quarter.
  • Across five years, FCF Margin topped out at 1383.43% in Q3 2022 and bottomed at 13047.53% in Q1 2021.
  • Average FCF Margin over 5 years is 2706.36%, with a median of 444.0% recorded in 2023.
  • The sharpest move saw FCF Margin tumbled -545663bps in 2021, then surged 826156bps in 2023.
  • Year by year, FCF Margin stood at 8120.86% in 2021, then soared by 62bps to 3057.95% in 2022, then soared by 87bps to 393.45% in 2023, then soared by 101bps to 5.61% in 2024, then plummeted by -2046bps to 109.13% in 2025.
  • Business Quant data shows FCF Margin for NMTC at 109.13% in Q4 2025, 56.05% in Q3 2025, and 86.29% in Q2 2025.